The Federal Trade Commission’s investigation into pharmacy benefit managers has revealed a concentrated market dominated by six major PBMs, leading to high drug costs for patients and struggles for independent pharmacies. The FTC is preparing to sue CVS Caremark, Express Scripts, and Optum Rx over insulin prices related to secret rebate agreements. The report highlights how PBMs prioritize profits over patient care. Various bills targeting PBMs, including the Pharmacy Benefit Manager Transparency Act, have bipartisan support. Despite pushback from PBMs, there is momentum for legislative reforms to address rising prescription drug costs and ensure patient access to affordable healthcare.
Source link
The FTC Released a Scathing Interim Report on PBMs. What’s Next?
